Details for New Drug Application (NDA): 202414
✉ Email this page to a colleague
The generic ingredient in IRBESARTAN AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; irbesartan. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; irbesartan profile page.
Summary for 202414
| Tradename: | IRBESARTAN AND HYDROCHLOROTHIAZIDE |
| Applicant: | Macleods Pharms Ltd |
| Ingredient: | hydrochlorothiazide; irbesartan |
| Patents: | 0 |
Pharmacology for NDA: 202414
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
Suppliers and Packaging for NDA: 202414
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 202414 | ANDA | Macleods Pharmaceuticals Limited | 33342-057 | 33342-057-06 | 3 BLISTER PACK in 1 CARTON (33342-057-06) / 10 TABLET, FILM COATED in 1 BLISTER PACK |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 202414 | ANDA | Macleods Pharmaceuticals Limited | 33342-057 | 33342-057-07 | 30 TABLET, FILM COATED in 1 BOTTLE (33342-057-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG;150MG | ||||
| Approval Date: | Sep 27, 2012 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG;300MG | ||||
| Approval Date: | Sep 27, 2012 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
